Human Granulocyte Colonystimulating Factor Market
Human Granulocyte Colony-stimulating Factor
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Human Granulocyte Colony-stimulating Factor Market
Size and Growth
The Human Granulocyte Colony-stimulating Factor market is experiencing significant growth, driven by increasing cancer cases and advancements in therapeutics. Current market size estimates exceed $3 billion, with a projected CAGR of over 10% through 2030. Enhanced awareness of innovative treatments and regulatory support further bolster market expansion and investment opportunities. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Chugai Pharmaceutical
◍ Kyowa Hakko Kirin
◍ Sanway
◍ GenSci
◍ SL PHARM
◍ Kexing Bioproducts
◍ Qilu Pharmaceutical
◍ CSPC
◍ Wuzhong Pharmaceutical
◍ Quangang Pharmaceutical
◍ Huabei Pharmaceutical
◍ Harbin Pharmaceutical
◍ Amoytop Biotech
◍ Jiuyuan Gene Engineering
◍ Four Rings Biopharmaceutical
The Human Granulocyte Colony-stimulating Factor market features companies like Chugai Pharmaceutical and Kyowa Hakko Kirin, which develop advanced therapies. Firms such as CSPC and Qilu Pharmaceutical enhance market growth through innovative products. Notable sales figures include Kyowa Hakko Kirin: $1.3 billion, and CSPC: $2.5 billion. Request Sample Report
Market Segmentation
By Application
Hospital
Clinic
By Product
◍ 300μg/Dose
150μg/Dose
75μg/Dose
Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
